
Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Tew
Dr. William Tew is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from University of Rochester School of Medicine and Dentistry and has been in practice 18 years. He specializes in gynecologic cancer and hematologic oncology and is experienced in gynecologic oncology and geriatric assessment.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
NYU Grossman School of MedicineResidency, Internal Medicine, 1999 - 2003
University of Rochester School of Medicine and DentistryClass of 1999
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2027
NY State Medical License 2000 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Start of enrollment: 2004 Jan 01
- Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Start of enrollment: 2004 Jan 01
- Assessment Tool for Older Patients With Cancer Start of enrollment: 2006 Dec 19
- Join now to see all
Publications & Presentations
PubMed
- A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.Sara Moufarrij, Claire F Friedman, Samuel Freeman, Hunter Green, Nadeem R Abu-Rustum
Gynecologic Oncology. 2025-10-31 - Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?Tiffany Y Sia, Sara Moufarrij, Juliet Milani, Sarah Kane, Qin Zhou
Gynecologic Oncology. 2025-10-01 - 1 citationsNeoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Clinical Insights.William P Tew, Christina Lacchetti, Stéphanie Gaillard
JCO Oncology Practice. 2025-07-01
Journal Articles
- A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian CancerKaren A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHumana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:





